Answers are grounded in this paper and cite their sources.
Blinatumomab is an efficacious and well-tolerated treatment in patients with MRD-positive B-lineage ALL after intensive chemotherapy. T cells engaged by blinatumomab seem capable of eradicating chemotherapy-resistant tumor cells that otherwise cause clinical relapse.
No takes yet. Share an insight, caveat, or question.
Topp et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: